Study of Roxadustat (FG-4592) in Participants With End-Stage Renal Disease Receiving Maintenance Hemodialysis

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 161 participants.

Also called NCT01147666

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 161 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01147666
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01147666. Randomized; double masking; primary purpose treatment. Start 2010-05-17 (actual); primary completion 2012-10-15 (actual). Results posted on 2022-01-11.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study of Roxadustat (FG-4592) in Participants With End-Stage Renal Disease Receiving Maintenance Hemodialysis
Condition
End Stage Renal Disease
Condition
Anemia
Intervention (Drug)
Roxadustat
Intervention (Drug)
Epoetin Alfa
Intervention (Other)
Placebo
Lead sponsor
Kyntra Bio (class: industry)
Collaborator
AstraZeneca (class: industry)
Collaborator
Astellas Pharma Inc (class: industry)

Record details

Record id
cardio:ct-nct01147666
Content hash
f6ba3a5ed85b4ee20d08b3ba078438dfd59d60c6349ebfa1da3b16da5b44d9dd